Day 2 Program

General Session 1

Day 2: December 9, 2026

9:30 AM–11:45 AM CST

Hall 1

Session Details

Moderator

William M Sikov, Women and Infants Hospital of Rhode Island and Warren Alpert Medical School of Brown University, Providence, RI

Moderator

Laura M. Spring, Mass General Brigham Cancer Institute, Boston, MA, MA

GS1-1

External Validation of a Causal Multi-Modal AI Model for Prognosis and Chemotherapy Benefit in Node-Negative HR+/HER2- Breast Cancer Patients: Analysis of TAILORx

Nancy Chan, NYU Langone Health, New York, NY

GS1-2

Blinded validation of a causal multi-modal AI model in postmenopausal, node-positive, HR+ breast cancer: analysis of SWOG-8814

Alastair M Thompson, Baylor College of Medicine, Houston, TX

GS1-3

Discussant for 1411 and 1420

Frederick M. Howard

GS1-4

Efficacy results of the SWOG-S1418 / NRG Oncology BR006 randomized Phase III trial evaluating adjuvant Pembrolizumab for triple negative breast cancer with residual disease after neoadjuvant chemotherapy.

Lajos Pusztai, Yale School of Medicine, New Haven, CT

GS1-5

Neoadjuvant Famitinib in combine with Camrelizumab and chemotherapy in Triple Negative breast cancer (BCTOP-T-N01): a multicentre, randomized, phase 3 trial

Jun-Jie Li, Fudan University Shanghai Cancer Center, Shanghai, China

GS1-6

Results of phase II NeoTRACT trial: Neoadjuvant tumor infiltrating lymphocyte- and response-adapted chemoimmunotherapy for triple-negative breast cancer (TNBC)

Priyanka Sharma, University of Kansas Medical Center, Westwood, KS

GS1-7

Discussant for 916

Marleen Kok, Netherlands Cancer Institute, Amsterdam, Netherlands

GS1-8

First-line sacituzumab tirumotecan (sac-TMT) vs chemotherapy in unresectable recurrent or metastatic triple-negative breast cancer (TNBC) with PD-L1 CPS <10 or prior early-stage PD-(L)1 exposure: randomized phase 3 OptiTROP-Breast03 trial

Lei Fan, Fudan University Shanghai Cancer Center, Shanghai, China